Literature DB >> 26870897

Long-term follow-up of endoscopic third ventriculostomy performed in the pediatric population.

Matthew G Stovell1, Rasheed Zakaria2, Jonathan R Ellenbogen1,2, Mathew J Gallagher2, Michael D Jenkinson2, Caroline Hayhurst3, Conor L Mallucci1.   

Abstract

OBJECTIVE Endoscopic third ventriculostomy (ETV) is an effective treatment for obstructive hydrocephalus and avoids the risk for foreign-body infection associated with ventriculoperitoneal (VP) shunts. The short-term failure rate of ETV strongly depends on the indications for its use but is generally thought to be lower in the long term than that of VP shunts. However, few studies are available with long-term follow-up data of ETV for hydrocephalus in children. The authors reviewed the long-term success of ETV at their institution to investigate the rate of any late failures of this procedure. METHODS Between April 1998 and June 2006, 113 children (including neonates and children up to 16 years old) had primary or secondary ETV for different causes of hydrocephalus. The patients' medical records and the authors' electronic operation database were reviewed for evidence of additional surgery (i.e., repeat ETV or VP shunt insertion). These records were checked at both the pediatric and adult neurosurgical hospitals for those patients who had their care transferred to adult services. RESULTS The median length of follow-up was 8.25 years (range 1 month to 16 years). Long-term follow-up data for 96 patients were available, 47 (49%) of whom had additional ETV or VP shunt insertion for ETV failure. Twenty patients (21%) had a second procedure within 1 month, 17 patients (18%) between 1 and 12 months, 7 patients (7%) between 1 and 5 years, and 3 patients (3%) between 5 and 8 years. CONCLUSIONS In the authors' series, ETV had an initial early failure rate for the treatment of pediatric hydrocephalus as reported previously, and this rate significantly depended on patient age and hydrocephalus etiology. Once stabilized and effective, ETV appeared to be durable but not guaranteed, and some late decline in effectiveness was observed, with some ETV failures occurring many years later. Thus, successful ETV in children cannot be guaranteed for life, and some form of follow-up is recommended long term into adulthood.

Entities:  

Keywords:  CSF disorders; ETV; ETV = endoscopic third ventriculostomy; ETVSS = ETV Success Score; VP = ventriculoperitoneal; follow-up; hydrocephalus; long term

Mesh:

Year:  2016        PMID: 26870897     DOI: 10.3171/2015.11.PEDS15212

Source DB:  PubMed          Journal:  J Neurosurg Pediatr        ISSN: 1933-0707            Impact factor:   2.375


  5 in total

1.  External validation of the ETV success score in 313 pediatric patients: a Brazilian single-center study.

Authors:  Leopoldo Mandic Ferreira Furtado; José Aloysio da Costa Val Filho; Eustaquio Claret Dos Santos Júnior
Journal:  Neurosurg Rev       Date:  2021-01-03       Impact factor: 3.042

2.  Management of hydrocephalus in pediatric metastatic tumors of the posterior fossa at presentation.

Authors:  Luc Le Fournier; Matthieu Delion; Maxime Esvan; Emilie De Carli; Céline Chappé; Philippe Mercier; Philippe Menei; Laurent Riffaud
Journal:  Childs Nerv Syst       Date:  2017-05-11       Impact factor: 1.475

3.  Endoscopic Third Ventriculostomy: Role of Image Guidance in Reducing the Complications.

Authors:  Muhammad Samir Irfan Wasi; Salman Sharif; Yousuf Shaikh
Journal:  Asian J Neurosurg       Date:  2020-10-19

4.  Endoscopic third ventriculostomy in children with a fiber optic neuroendoscopy.

Authors:  Wenjun Shen; Hasan R Syed; Gurpreet Gandhoke; Roxanna Garcia; Tatiana Pundy; Tadanori Tomita
Journal:  Childs Nerv Syst       Date:  2017-12-16       Impact factor: 1.475

5.  Endoscopic third ventriculostomy for adults with hydrocephalus: creating a prognostic model for success: protocol for a retrospective multicentre study (Nordic ETV).

Authors:  Sondre Tefre; Alexander Lilja-Cyron; Lisa Arvidsson; Jiri Bartek; Alba Corell; Axel Forsse; Andreas Nørgaard Glud; Sami Abu Hamdeh; Frederik Lundgaard Hansen; Antti Huotarinen; Conny Johansson; Olli-Pekka Kämäräinen; Tommi Korhonen; Anna Kotkansalo; Nadia Mauland Mansoor; Eduardo Erasmo Mendoza Mireles; Rares Miscov; Sune Munthe; Henrietta Nittby-Redebrandt; Nina Obad; Lars Kjelsberg Pedersen; Jussi Posti; Rahul Raj; Jarno Satopää; Nils Ståhl; Sami Tetri; Lovisa Tobieson; Marianne Juhler
Journal:  BMJ Open       Date:  2022-01-31       Impact factor: 2.692

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.